Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD-NE vs Epidyolex PK Study
NCT06578455Phase 1Completed
- Sponsor
- DSM-Firmenich
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol (4 arms), sponsored by DSM-Firmenich. Primary endpoints: Maximum Concentration in Plasma, Area Under the Plasma Concentration-Time Curve from 0 to 24 hours and 3 more. Started Aug 2024; status: completed.
02
Drugs
cannabidiol
Beyond the preview
Go deeper on NCT06578455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578455.